| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
Etoricoxib impurity 17 does not have a defined biological target as it is an inactive impurity. The parent drug etoricoxib is a highly selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of approximately 1 microM for COX-2 and >100 microM for COX-1, giving it a >100-fold selectivity ratio. By inhibiting COX-2, etoricoxib reduces the production of pro-inflammatory prostaglandins, providing analgesic and anti-inflammatory effects. This impurity is not intended for pharmacological studies; it serves only as an analytical standard for quality control.
|
|---|---|
| ln Vitro |
Etoricoxib impurity 17 has no reported in vitro biological activity. It is not tested for COX-2 or COX-1 inhibition. Its sole purpose is as a chemical reference material for analytical quality control. The impurity is used to prepare calibration standards for HPLC or LC-MS/MS to quantify its levels in etoricoxib batches, ensuring drug purity and compliance with regulatory standards. No cell-based or functional assays are performed with this compound.
|
| ln Vivo |
No in vivo activity data are available for Etoricoxib impurity 17. It is not administered to animals for efficacy studies. The compound is used exclusively as a reference standard in chemical analysis. Its presence in etoricoxib drug substance is controlled at low levels (typically <0.1%) to ensure safety and compliance with ICH guidelines. For research use only.
|
| Enzyme Assay |
Not applicable. Etoricoxib impurity 17 is an analytical reference standard, not a drug candidate. For non-cellular characterization, a standard HPLC method is used: dissolve the compound in methanol or acetonitrile to 0.5-1 mg/mL. Inject onto a C18 column (250×4.6 mm, 5 microm). Mobile phase: 0.1% formic acid in water (A) and acetonitrile (B). Gradient: 20% B to 70% B over 25 min. Flow rate: 1.0 mL/min, UV detection at 254 nm. Retention time is approximately 12-15 min. For LC-MS/MS, positive ESI mode, m/z 274 [M+H]+. Purity >95% (HPLC). No enzyme/receptor binding assays.
|
| Cell Assay |
Not applicable. Etoricoxib impurity 17 is not used in cell-based biological assays. It is a chemical reference standard for analytical quality control. For cell culture studies, the parent drug etoricoxib would be used, but not this impurity. For research use only.
|
| Animal Protocol |
Not applicable. Etoricoxib impurity 17 is not used for in vivo animal studies. It is a reference standard for chemical analysis. No animal dosing or efficacy studies are performed with this compound. For research use only.
|
| ADME/Pharmacokinetics |
Not applicable. Etoricoxib impurity 17 is a pharmaceutical impurity, not a drug candidate; its pharmacokinetic properties are not characterized. The parent drug etoricoxib has oral bioavailability of ~100%, Tmax of ~1-2 h, terminal half-life (t½) of ~22 h, and is extensively metabolized by CYP3A4. For storage, powder at -20degC for up to 3 years, protected from light and moisture. Solubility: DMSO, methanol. Appearance: solid. Purity >95% (HPLC).
|
| Toxicity/Toxicokinetics |
No toxicity data are available for Etoricoxib impurity 17 as a pure compound. In pharmaceutical manufacturing, the allowable limit of this impurity is controlled based on ICH guidelines (typically ≤0.1% for unspecified impurities). Standard laboratory safety precautions for handling chemical reference standards should be followed: avoid inhalation, ingestion, skin/eye contact; use PPE (gloves, lab coat, safety goggles); work in a fume hood. For research use only-not for human use.
|
| Additional Infomation |
CAS: 307531-95-9. Molecular formula: C15H15NO2S, molecular weight: 273.36. IUPAC name: 1-(6-methylpyridin-3-yl)-2-(4-(methylsulfinyl)phenyl)ethan-1-one. Also known as Etoricoxib Impurity 17. Purity: typically >95% by HPLC. Appearance: solid powder. Storage: -20degC. Use: pharmaceutical reference standard, impurity profiling, method validation. Not for human use. For research only.
|
| Molecular Formula |
C15H15NO2S
|
|---|---|
| Molecular Weight |
273.36
|
| CAS # |
307531-95-9
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6582 mL | 18.2909 mL | 36.5818 mL | |
| 5 mM | 0.7316 mL | 3.6582 mL | 7.3164 mL | |
| 10 mM | 0.3658 mL | 1.8291 mL | 3.6582 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
